The Institute of Cancer Research/LinkedIn
May 31, 2025, 18:39
Pembrolizumab Helps Head and Neck Cancer Patients Live Years Longer Cancer-Free – The Institute of Cancer Research
The Institute of Cancer Research shared a post on LinkedIn:
“BREAKING:
Researchers at the ICR have shown that pembrolizumab, an immunotherapy drug, helps head and neck cancer patients live years longer cancer-free.
The immunotherapy also hunts down cancer trying to spread – after three years, the risk of cancer returning elsewhere in the body was 10 per cent lower than for patients on standard treatment. The phase III KEYNOTE-689 trial was led by University of Washington – School of Medicine, USA and funded by MSD.
Read about the results of the trial, presented at the American Society of Clinical Oncology annual meeting.”
-
Challenging the Status Quo in Colorectal Cancer 2024
December 6-8, 2024
-
ESMO 2024 Congress
September 13-17, 2024
-
ASCO Annual Meeting
May 30 - June 4, 2024
-
Yvonne Award 2024
May 31, 2024
-
OncoThon 2024, Online
Feb. 15, 2024
-
Global Summit on War & Cancer 2023, Online
Dec. 14-16, 2023
May 31, 2025, 17:48
May 31, 2025, 17:47
May 31, 2025, 17:39
May 31, 2025, 17:38